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Abstract 
 
Background 
‘Treatment burden’, defined as both the workload and impact of treatment regimens on function and well-
being, has been associated with poor adherence and unfavourable outcomes. Previous research focused 
on treatment workload but our understanding of treatment impact is limited. This research aimed to 
systematically review qualitative research to identify: 1) what are the treatment generated disruptions 
experienced by patients across all chronic conditions and treatments? 2) what strategies do patients employ to 
minimise these treatment generated disruptions? 
 
Methods and Findings 
The search strategy centred on: treatment burden and qualitative methods. Medline, CINAHL, Embase, 
and PsychINFO were searched electronically from inception to Dec 2013. No language limitations were set. 
Teams of two reviewers independently conducted paper screening, data extraction, and data analysis. Data 
were analysed using framework synthesis informed by Cumulative Complexity Model. Eleven papers 
reporting data from 294 patients, across a range of conditions, age groups and nationalities were included. 
Treatment burdens were experienced as a series of disruptions: biographical disruptions involved loss of 
freedom and independence, restriction of meaningful activities, negative emotions and stigma; relational 
disruptions included strained family and social relationships and feeling isolated; and, biological disruptions 
involved physical side-effects. Patients employed “adaptive treatment work” and “rationalised non-
adherence” to minimise treatment disruptions. Rationalised non-adherence was sanctioned by health 
professionals at end of life; at other times it was a “secret-act” which generated feelings of guilt and impacted 
on family and clinical relationships. 
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Conclusions 
Treatments generate negative emotions and physical side effects, strain relationships and affect identity. 
Patients minimise these disruptions through additional adaptive work and/or by non-adherence. This affects 
physical outcomes and care relationships. There is a need for clinicians to engage with patients in honest 
conversations about treatment disruptions and the ‘adhere-ability’ of recommended regimens. Patient-
centred practice requires management plans which optimise outcomes and minimise disruptions. 
 
 
 
Introduction 
Living with and managing chronic illness requires hard work as patients seek to cope with, adapt to 
and minimise the physical, emotional and biographical impacts of the disease [1, 2]. Navigating 
services, interacting with health professionals and enacting treatments also creates work and may 
generate disruptions to patients’ wellbeing and functioning [3].This has been termed treatment burden 
or burden of treatment (BoT). 
Conceptual clarity is vital in research and practice. Careful delineation of the causes, components and 
consequences of BoT will enhance attempts to ameliorate it; however, BoT is an emergent concept 
which researchers are still working to define. Some have conceptualised treatment burden as the 
physiological side-effects (e.g. pain, nausea, dizziness, rash) of medication, surgery or other therapies 
[4–6], whilst others have explored BoT from the perspective of psychosocial consequences [7] and 
reductions in quality of life [8–12]. Yet others have focused on the workload arising from treatment 
regimens [12], conceptualising treatment burden as “the self-care practices that patients with chronic 
disease must perform to enact management strategies and respond to the demands of healthcare 
providers and systems”. Treatment work load is situationally specific; the nature of work and its 
associated burdens vary in different countries, partly attributable to differences in the structure and 
funding of healthcare systems [3]. The focus on ‘treatment workload’ has usefully led to the application 
of Normalisation Process Theory (NPT) [13] as an analytical framework and the development of a 
taxonomy of physical, cognitive and interactional tasks contributing to treatment burden [11]. Further 
re- search, using qualitative data, has defined treatment burden as both the workload of treatments and 
their impact on “patient functioning and well-being” [3]. Analysing qualitative interviews (n = 32), across 
a range of conditions, Eton et al identified the “work patients must do”, “the strategies and tools which 
facilitate self-care” and the “factors that exacerbate burden”. Sav, King [14] conducted a concept 
analysis of treatment burden in a range of chronic illnesses. 
They described the “dynamic and multidimensional” attributes of BoT which consisted of “both 
subjective and objective elements” and highlighted the need for a focus beyond workload. A series of 
antecedents (e.g. ‘patient characteristics’ and ‘health care systems’) and consequences (e.g. 
‘adherence’, ‘resource use’) were also characterised. Whilst the complexity and fluidity of treatment 
burden were acknowledged, the conclusions were limited by the paucity of inductive, qualitative 
research exploring patient accounts included (n = 1 paper). Further re- search to describe and classify 
treatment generated disruptions is required. 
In this research we set out to build and extend the body of work on conceptualising treatment burden, 
across all chronic conditions and treatments, by systematically reviewing empirical qualitative research 
to answer the following questions: 1) what are the treatment generated disruptions experienced by 
patients across all chronic conditions and treatments? 2) what strategies do patients employ to minimise 
these treatment generated disruptions?. 
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Table 1. PICOS table summarising study rationale. 
Participants Humans, any age, any condition 
Interventions Any treatment 
Comparisons Not applicable 
Outcomes Treatment burden or Burden of treatment 
Study design Qualitative data collection and qualitative analysis of patient perspectives 
 
Table 1 summarises the PICOS rationale. 
 
Methods 
Search strategy 
Qualitative studies using methods involving direct patient contact, such as interviews and focus 
groups, and seeking to understand the patient experience of treatment burden across all conditions 
and treatments were sought. Searching and screening were conducted according to the PRISMA 
statement (See S1 PRISMA Checklist) [15]. The data bases Medline, CINAHL, Embase, and 
PsychINFO were searched electronically. No date limitations were set but “language” was restricted to 
English or Portuguese as there were no resources for translation. We aimed to identify all papers that 
used the terms “treatment burden” or “burden of treatment”  in their title or abstract. Given that the 
systematic identification of qualitative research is problematic [12, 16] we did not limit our initial search 
by research method. Rather, identification of qualitative papers was undertaken during the blinded 
screening process. Initial searches were conducted in June 2012 and were updated in April 2014. 
 
Data screening, extraction and analysis 
Title, abstract and full paper screening were undertaken independently by three researchers (AJM; 
ACG; CA) using a data-extraction proforma designed and piloted by the team. Inclusion was accepted 
by concordance; a third party (SD or KH) resolved any disagreements. Duplicates and any papers not 
addressing treatment burden at the level of the patient were excluded (e.g. global economic treatment 
burden; treatment burden on services). Papers were included only if they utilised recognised inductive 
qualitative data collection and analysis methods. Quantitative research, systematic reviews, qualitative 
syntheses, opinion pieces and papers reporting qualitative methods but containing no qualitative data 
(e.g. quotations or thematic frame- works) were excluded. 
Qualitative research is interpretative: data therefore included verbatim quotes and authors’ 
interpretative comments and were extracted from the findings/results and discussion sections of 
papers [11]. Data were analysed using framework synthesis [17, 18] using a coding frame- work 
informed by the Cumulative Complexity Model (CCM) [19]. The CCM proposes that the balance 
between patient workload (treatment, ‘everyday’ and occupational tasks) and their capacity to 
undertake that work influences access and adherence to treatments and consequent health outcomes. 
This model was appropriate to our focus on understanding how BoT impacts on “patient functioning and 
well-being” [3] and the factors contributing to and shaping these experiences. We used Shippee et al’s 
categories (e.g. capacity, workload, adherence etc.) to generate our framework but did not pre-
determine the existence of their proposed inter- 
category relationships. 
Framework synthesis uses a two staged approach; data extraction and management into pre-
determined categories and then thematic analysis to identify patterns of data within and 
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between categories [17]. A data management framework, with 4 well defined categories (work- load, 
capacity, treatment impact and engagement/adherence) was developed. Data assignment was 
undertaken by pairs of researchers (SD/CA: papers 1–4; KH/RO: papers 5–8; SD/AM: papers 9–11) who 
coded blind and then met in pairs to discuss and agree categorisation. Finally, each pair presented their 
coding to the other and any issues of contention were discussed and agreed by the whole team. 
The second phase of framework synthesis involved thematic analysis of data categorised within the 
‘treatment impact’ category. Two researchers (SD/KH) conducted this analysis separately, and then 
through collaborative discussion, using paper based labelling, fragmenting, comparing and grouping 
[20] until a clear taxonomy of the components of treatment impact were agreed. Finally, relationships 
between the treatment impacts and those proposed previously (e.g. capacity, workload and adherence) 
were identified using constant comparison, team brainstorming and diagrammatic modelling. Our 
synthesis generated both second-order (interpretations offered by the original researchers) and third-
order constructs (new interpretations beyond those offered in individual studies) [21]. 
Our emerging synthesis indicated that people seek healthcare not simply to relieve physical or 
emotional symptoms but because those symptoms stop them from doing what they want (e.g. running 
or hiking) and being who they want to be (a professional athlete, a member of the rambling club or an 
optimistic person). In finalising our synthesis model we therefore called upon Sen’s capability 
approach [22] which considers the genuine opportunities (capabilities) people have to achieve the kind 
of lives they value: to feel like, do what and be who they want to be. Treatment burdens were therefore 
considered to be any treatment generated disruption in people’s ability to feel, do or be who they 
wanted to be. 
 
Quality appraisal 
Quality appraisal was undertaken using the Critical Appraisal Skills Programme [23] criteria for 
qualitative studies. Quality appraisal was independently conducted by two researchers (SD and KH) 
and answers compared and discussed. Studies were not, however, excluded on the basis of quality. 
 
Enhancing analytic credibility through expert patient review 
Analytic relevance and credibility was enhanced by inclusion of a lay representative in the study team 
(RP). RP brought the following expertise to the team: i) experience of a long-term condition (stroke); ii) 
pre-stroke expertise in analysing complex systems and processes iii) leadership of local and national 
patient organisations. RP critiqued and challenged the emergent analysis, reflecting on its relevance to 
his own experience and those of other people with long- term conditions that he worked with. 
 
Results 
Retrieved studies 
The initial (April 2012) and updated (April 2014) searches identified a total 1177 papers; after removal 
of duplicates, 774 titles and abstracts were screened for relevance; 368 full text articles were assessed 
for eligibility; 11 papers which used qualitative methods and analysis and which presented data on 
patients’ perspectives of treatment burden were included. Fig 1 presents the PRISMA flow diagram 
indicating the inclusion and exclusion of papers at each stage of the screening process. 
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Fig 1. PRISMA flow diagram indicating inclusion and exclusion criteria of papers at each stage of screening. 
doi:10.1371/journal.pone.0125457.g001 
 
 
 
 
Study details 
 
Details of included studies are presented in Table 2. A range of qualitative methods were reported:ten 
used semi-structured interviews, either alone [3, 7, 24–28], with focus groups [29,30] or with structured 
measures [8]; one conducted secondary analysis of existing qualitative data [11]. Included papers 
addressed a range of chronic conditions across the life-course (aged 8–96 years) including: adults with 
spasmodic dysphonia [7]; chronic heart failure (CHF) [11];conditions requiring percutaneous endoscopic 
gastrostomies (PEG) [8]; chronic kidney disease(CKD) [24, 28]; people with limited life expectancy due to 
various conditions [29]; adolescents/young adults with cystic fibrosis (CF) [25] and tuberculosis (TB)[30]; 
children with Primary Ciliary Dsykinesia (PCD)[26] and, a range of chronic conditions [3, 14]. The 
conditions varied in terms of the severity and impact of disease, the likelihood and immediacy of life 
threat, and the invasiveness and criticality of treatments. Studies were undertaken in: the UK [8, 11, 24, 
26], US [3, 7, 25, 29], Nepal [30], Australia [27], and Greece[28]. All of the papers included a mix of 
genders. A variety of qualitative analysis methods were used; all sought to identify common themes 
raised by participants. 
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Quality appraisal 
Papers were moderate to high quality. The sampling strategy, relationship between researchers and 
participants and detailed consideration of ethical issues were the weaker elements of 
these papers. 
 
Thematic findings 
The synthesis generated eight second-order constructs related to the “negative impacts of treatment on 
functioning and well-being” which we collated into three third-order constructs “bio- graphical, relational 
and biological treatment disruptions”. Table 3 presents these 2nd and 3rd order constructs and identifies 
where evidence for each can be found. The synthesis generated a further two third-order constructs 
related to the strategies employed by patients to minimise the disruptions to their valued capabilities: 
“adaptive treatment work” and “rationalised non- adherence”. This is also presented graphically in Fig 2. 
Biographical disruption.   The concept of biographical disruption was first defined by Bury [2] to 
explain the disruption to a person’s self-narrative and self-concept that results from 
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Fig 2. The biographical, relational and biological disruptions generated by treatment burdens and the strategies of adaptive 
work and rationalised non-adherence which patients employ to minimise these. 
 
 
chronic illness [31]. In our review, treatments were similarly identified as a cause of biographical 
disruptions impacting on people’s sense of self, negatively affecting their emotions, their sense of 
freedom and their ability to engage in meaningful activities. The majority of studies [7, 8, 24–28, 30] 
highlighted patients’ concerns about the impact treatments had on how they were seen by others and how 
they viewed themselves. Stigma was reported when enacting treatments (e.g. carrying a portable feeding 
system) or treatment consequences (altered voice following BOTOX) increased the visibility of otherwise 
hidden illnesses; when treatments involved others observing bodily sites, processes or excretions that 
were intimate or generated repulsion (e.g. sputum clearance; changing PEG tubes); or, when physical 
side-effects were embarrassing and impacted on identity (e.g. weak breathy voice post-botox): 
 
B.W. adjusts her work activities because of how people respond to her when she is in the breathy voice 
phase [post-botox]: “When you have the Marilyn Monroe voice, you don’t go into important situations. 
They just discredit what you say. Even my friends who are completely on my side [say] how can we take 
you seriously? It’s just too funny to listen to Mar- ilyn Monroe [her identity with the breathy voice].” [7] 
 
Loss of freedom and independence was a recurring theme in six of the reviewed papers [7, 8, 11, 25, 
27, 30]. This included the practical loss of freedom conferred by virtue of the time taken to perform 
treatments and being physically constrained by technologies such as nebulisers, dialysis and feeding 
machines. Loss of freedom also incorporated the more existential sense of not being “carefree”. 
The need to constantly plan treatments into daily regimes was viewed as loss of spontaneity, particularly 
amongst adolescents with CF: a time in the life-course normally associated with increased freedom and 
spontaneity.  
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The need to undertake regular treatments and/or monitor treatment out- comes served as a constant 
reminder of being ill, even when symptoms had been eradicated. 
 
I used to take detailed notes (of my treatments and outcomes) and I thought later on “this is excessive”... 
When I was thinking about my voice all the time.. .it turned out to be more of a pressure thing. [7] 
 
The need to plan ahead was also linked to the problem of uncertainty [7, 8, 11, 26, 28–30] as 
unpredictable treatment outcomes and side-effects created the need for a life lived with contingency 
plans. Some uncertainty arose from the illness itself, however, some was directly attributable to the 
treatment. Causes of uncertainty included technological failures (e.g. feeding tubes becoming blocked), 
unpredictable responses to medication (botox), lack of easily observable treatment benefits (CHF, CF, 
TB), uncertainty about long term side-effects (CHF and botox), how to administer treatments (PEG 
feeding) or the purpose or duration of the regime (TB). 
Contradictory advice from health staff was also a major cause of uncertainty [28]. 
Negative emotional consequences were reported in all studies in this review. Emotional responses 
were highly variable and related to the individual patient and their social and treatment context. Patients 
responded with frustration or anger when they perceived treatment generated burdens to be avoidable 
e.g. when a lack of staff expertise or knowledge caused preventable complications or wasted patients’ 
time or when scheduling of treatments and appointments was hindered by inflexible services [3, 7, 8, 11, 
24, 27, 30]. Anxiety, fear and worry were highlighted in several studies [3, 7, 8, 27, 28, 30]. People worried 
about the immediate and long-term risks of treatment, the future effectiveness of treatments, 
experiencing pain, losing employment, being stigmatised by others, the financial implications of 
treatment and becoming a burden to families. Guilt was experienced in relation to the physical workload or 
financial costs of treatment incurred by patients’ families and by patients who were unable to adhere to 
treatment recommendations; however, this could be exacerbated or ameliorated by the quality of 
relationship between patients and professionals. 
 
“[The doctor] was really funny and outgoing and really nice and that helped a lot getting me back into clinic. 
Because I don’t come as often asI should, but I come a lot more than I used to.” [25] 
 
The majority of studies [7, 8, 11, 25–27, 29] identified the reduction or loss of valued activities as a key 
element of biographical disruption. People receiving Botox injections weighed up when to have further 
injections based on the impact it would have on their valued activities. 
For instance one woman, who experienced breathlessness post-Botox, would not have the injection in 
the summer when she liked to go hiking, whilst another tried to plan the injection to avoid Christmas and 
other critical time points. People with CHF also reported avoiding travel- ling if they had taken diuretics or 
avoided diuretics if they wanted to travel, and adolescents with CF made similar decisions modifying 
their time-consuming treatment regimes so that they could do the things they wanted. 
 
Holding down a full time job and living life normally—time is a big thing.. .I would rather do all the things I 
want to do instead of sit home and do all the things I should and miss out on a bunch of stuff... I am quality 
over quantity. [25] 
 
Some treatments were not easily modified, for instance people undergoing PEG feeding or 
haemodialysis could not stop or reduce their treatments without major consequences. However, 
substantial restrictions to important activities were often deemed acceptable because the treatment was 
“life-saving”. 
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It (PEG) dominates life—it’s in use the greater proportion of the 24 hours. It dominates movement, but we’re 
happy with it—if it wasn’t for the PEG she wouldn’t be here.’ [8] 
 
Relational disruption. The negative impact of treatments on valued relationships was an- other 
common theme in the reviewed studies. 
Treatments generated feelings of isolation: for instance, people with TB hospitalised far from family 
and friends; others had restrictive home-based regimes (PEG feeding, dialysis); and, children with PCD 
reported deliberately isolating themselves from friends to avoid the stigma of expectorating sputum. 
People requiring highly specialist treatments (e.g. PEG feeding and Botox) described isolation from 
appropriate professional support as a consequence of limited specialists in their community. This resulted 
in professional uncertainty about appropriate responses to complications, a lack of guidance about 
treatments and consequently, some patients experienced additional physical side-effects, emotional 
distress, and uncertainty. Potentially avoidable burdens were less well tolerated than those viewed as 
inherent to the treatment. 
 
When he first had the PEG they (nurses on the ward) pulled the curtains round the bed and called me 
back. They told me, ‘You’ll be doing all this tomorrow’. There was just this one short instruction on the last 
night in hospital. He came home and nobody came to help us. The district nurse had gone sick. And we 
had the baby in the house as well. My daughter had just gone into hospital with the afterbirth retained—
she was in two weeks. The baby was two weeks old. There was no help at all. You just had to manage. 
[8] 
 
Parents reported the strain that could arise in relationships with children [26]. Children with PCD 
often had differing opinions from their families on the quality and frequency with which they engaged in 
their physiotherapy and nebuliser regimes. Some parents suggested their children were “lazy” and 
needed “nagging” which created tension in the relationship and emotional impacts for both parents and 
children. 
Relationship strain was also evident when time or financial resources spent on treatment had a 
negative impact on family leisure activities [26, 28] and some seriously ill people declined labour intensive 
treatments for fear of generating excessive family burden [24, 29]: 
 
.. . they were doing dancing and swimming, and we’ve just had to say look guys, I’m sorry, 
but we just can’t do anything, so nobody does anything, it’s just all therapy. [28] 
 
My daughter would have to bring me and that would mean [her] taking time off work.[24] 
 
Biological disruption. Treatments also generated biological disruptions in terms of physical side effects 
such as pain, nausea, dizziness, breathlessness, fatigue, infection which were re- ported in over half of the 
included studies [3, 7, 8, 11, 26–28]. The nature, severity and frequency of physical side-effects varied 
substantially across the studies and were related to the type of treatment received. The PEG feeding 
study described the greatest range of both type and severity of symptoms. This may be due to the 
invasive, restrictive and technically complex nature of the intervention. However, the study on dialysis 
(which is also invasive, restrictive and complex) did not discuss any physical symptoms. 
The extent of perceived biological disruption varied from person to person: the same treatment could 
generate symptoms perceived as intolerable by some and relatively minor by others: 
 
One participant described intubation saying, “If (the tube] doesn't go in right, they cut you up. You bleed, 
you're hurting, so on and so forth. Once it is in you can't talk. Your mouth is dry and it hurts, even when 
they take it out. In contrast, another participant, pointing out that he was not conscious at the time he was 
intubated, said, "at no time did I know that [the tube] was going in.. . . I do remember waking up after 
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several days... . It did annoy me, but not to the point of hurting." [29] 
 
The severity of physical side-effects did not seem to be directly associated with perceived burden; 
rather it was the impact that physical side effects (and indeed other types of burden) had on people’s 
ability engage in meaningful activities and on their personal identity that was most pertinent. 
The synthesis highlighted not only how treatment burdens were experienced by patients but also the 
strategies patients used to minimise and manage the capability disruptions generated by treatment. Two 
third-order constructs were identified: “rationalised non-adherence”, strategies directed at modifying the 
treatment; and, “adaptive treatment work”, strategies directed at modifying the self. 
Rationalised non-adherence. Rationalised non-adherence, which describes patients’ intentional partial 
or total non-adherence to treatment recommendations with the aim of minimising biographical, relational 
or biological disruptions, was reported in the majority of studies [7, 8, 11, 24–29]. Some patients reported 
‘trial and error experiments’ with the timing or dosage of medications [11, 27]. Patients with CF and PCD 
[25, 26] substituted boring or difficult physiotherapy with more enjoyable sporting activities which they 
reframed as “treatments”. They also admitted using rationalised non-adherence as a strategy for 
maintaining control and feeling carefree. One woman admitted not getting the next Botox injection in the 
summer because she would rather tolerate the voice deficit than become breathless and not be able to 
go hiking [7]. Thus, rationalised non-adherence was situational and variable over time depending on the 
relevant competing priorities in people’s lives. Most rationalised non-adherence decisions appeared to 
have been taken by patients without much discussion with Health Care Professionals (HCPs) and actively 
concealed from them. When rationalised non-adherence was revealed, HCPs often expressed 
disappointment or disapproval and tried to persuade patients to adhere. This often resulted in patients 
feeling guilty or not understood. An exception to this was treatments offered at the end of life. In these 
cases HCPs often helped people to make decisions about avoiding or withdrawing invasive treatments 
such as dialysis or assisted ventilation[24, 29]. Clinicians working with people at end of life appeared 
comfortable with facilitating and sanctioning ‘rationalised non-adherence decisions’ in order to reduce 
BoT and maximise quality of life. 
Adaptive treatment work. “Adaptive treatment work” describes the biographical, sentimental and 
relational work that patients and families engaged in as they sought to psychologically normalise 
treatments to their lives and their lives to the treatment. Whilst rationalised non-adherence involved 
changing or abstaining from treatment, adaptive treatment work involved changing how patients saw 
themselves or were seen by others. 
Patients’ use of strategies to prevent or minimise emotional distress was common through- out these 
studies. We refer to this as sentimental work. Some patients sought information and reassurance from 
family, on-line reports, or other patients to reduce their emotional distress. Others used “mental 
strategies” such as distraction, social comparison and psychological preparation. Adolescents with CF 
[25] described a process of ‘purposeful forgetting’ to minimise the emotional impact of treatments whilst 
people with CKD [28] talked about the need to ‘be grown up’ about treatments, to keep the ‘desire to be 
normal at bay’ and develop a ‘healthy mental attitude’. 
 
Have a healthy mental attitude towards it . . .  because if you let it get you down you know it could quite 
easily destroy you.. .at least you are still alive and at least there is hope. [28] 
 
Duration of illness seemed to play a part in enabling people to psychologically adjust to and embed 
treatments into lifestyles: 
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I’d recommend the PEG to anyone. You could work with it. I do lots of woodwork (he made his garden 
gates) and gardening . . .  it shouldn’t affect you . .  . it’s not so bad when you’ve never been well. It must be 
very hard for people who’ve always been well, but I’ve been ill for 50 years. [8] 
 
People also engaged in biographical work, using reframing to help them maintain a valued identity. 
One woman adopted new crafts, allowing her to reframe how she and others saw her ‘bedbound’ 
lifestyle from “being lazy” to being “productive. Others framed themselves as “fighters” or “survivors” to 
help them bear treatment side-effects. 
Relational work with family and friends was key to minimising the negative impacts of treatment on 
patients. This included performing treatments in secret and managing others’ expectations of their 
abilities. 
 
I don’t think people understand it (the effects of BOTOX). There are really understanding people and then 
others, it’s like ‘well you talk most of the time so why can’t you do that [now]?’ 
.. . And I’ve tried to explain that the toxin wears off and so that’s a real dilemma. [7] 
 
Fig 2 summarises the findings, indicating how the work of treatment generates biological, biographical 
and relational capability disruptions and identifying how these disruptions reduce patients’ capacity 
resulting in adaptive work to minimise the disruptions and restore capacity. 
 
Discussion 
Strengths and limitations 
This review is the first to explore and understand how treatments generate biological, bio- graphical and 
relational disruptions in a range of conditions across the life course and illness trajectory. Moreover, we 
have been able to identify additional secondary treatment work required to minimise those disruptions: 
the combined strategies of adaptation and rationalised non-adherence. Eleven empirical studies were 
included, reporting on the perspectives of treatment burden from a total of 294 patients, across a range of 
age groups and countries. However, there are a number of limitations to our review. For instance, 
although we adopted a thorough and comprehensive search strategy, some relevant studies may not 
have been identified. We wanted to focus on gathering emergent data from patients’ own perspectives 
(rather than more researcher-led deductive methods) and therefore included only papers which used 
inductive qualitative methods suitable for generating depth data. This may have resulted in the exclusion 
of potentially relevant data gathered using structured postal, on-line or telephone surveys. Further, we 
restricted our search to English and Portuguese reports as we had no resources for translation. 
However, we consider our analysis to have produced an integrated model with sufficient explanatory 
power to explain the relationships between treatment workload, capacity, disruptions and adherence. 
The quality of included studies may affect the validity of our findings: although we undertook quality 
review of all relevant studies, in the absence of consensus on the best way to appraise qualitative 
research [32], and because we wanted to maximise the reach and comprehensiveness of our findings, 
we did not exclude on this basis. All aspects of data extraction, quality appraisal and data analysis were 
conducted by teams of two researchers, with a third party for disagreements. This minimised researcher 
bias and enhanced analysis. Framework analysis provided a robust theoretical underpinning, using 
existing models of treatment burden such as NPT and the cumulative complexity model to inform 
analytical de- velopment. We consider this an effective approach but acknowledge that a priori 
frameworks risk forcing data inappropriately. We sought to minimise this risk, deliberately moving from 
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our initial deductive use of these a priori models (to fractionate and manage the data) into inductive 
thematic analysis specifically focussed on the perceived impact of treatment burden and the strategies 
employed to manage or reduce this. A further strength of this work is the inclusion of an expert patient 
researcher who contributed to the data analysis and writing of the paper, challenging underdeveloped 
conceptions and confirming the saliency of the findings to his own experiences and those of other people 
with chronic illness that he works with. 
 
Treatment generated disruptions 
Over recent years great strides have been taken to clarify conceptual and operational definitions of 
treatment burden. To date, much of this research has focused on the burden arising from treatment 
workload and the impact that workload has on the maintenance of normal activity. For instance, 
Gallacher’s work [11, 12] has highlighted the steps people take to embed treatments into their daily 
lives; Eton’s work [3] has considered the impact of patient functioning on wellbeing; and Sav’s work [14, 
27] has indicated that treatment burden consists of both objective elements, such as total workload and 
work complexity, and subjective, patient specific, elements. By synthesising the evidence across 
qualitative studies of treatment burden, our review has been able to expand further on these subjective 
elements and impacts. 
Our findings support the theory proposed by May, Eton [33], by showing that there are important 
factors, in addition to the complexity of treatments and the time involved in enacting them. This means 
that treatment burden is brought about by both the workload associated with treatment, and the impacts 
that workload and treatment complexity have on everyday life, valued daily activities and patient identity. 
In this way, we have shown that treatments and their total workload cause disruptions to a person’s 
biological, biographical and relational capacity. Despite finding, in line with previous literature [4–6], that 
treatments lead to biological disruptions in the form of physical symptoms and side-effects (such as pain 
and nausea), our findings also indicate that it is often not the severity of symptoms that determines how 
burden- some treatments are: rather, that the biographical and relational disruptions arising from those 
symptoms and side-effects have important impacts for patients. For instance, treatments had effects on 
identity, interaction with others and, in many cases, were associated with negative affective states. These 
affective states include anxiety, fear, anger, and frustration. In some cases these symptoms were severe 
and debilitating, further impacting on independence, relationships with others and ultimately, adherence 
to treatment regimens. Whilst previous work in this field has highlighted consequences such as fatigue 
[8, 27] and frustration [3, 7, 8, 11, 24, 27, 30], the results of this review indicate that the psychological 
and biographical consequences may be more far reaching and severe than initially considered. Further 
research is required to explore the impact and severity of negative affect and biographical disruption 
arising from treatment burden, in order to investigate relationships with quality of life, treatment 
adherence and outcome. 
 
Strategies for minimising treatment disruptions: adaptation 
This review also adds to the conceptual armoury of treatment burden theory by identifying two strategies 
for minimising treatment burden and disruptions: the first of these is adaptation. 
Building on previous research [1, 2, 11, 12, 31, 34] we identified three forms of adaptive work: 
1. Patients engaged in their own form of Sentimental work to manage the negative affective states 
associated with treatment burden. This involved self-soothing behaviours, managing contact and 
interactions with friends and family, and developing other strategies to minimise distress. This builds on 
the work of Corbin and Strauss [1] by extending the concept of 
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‘sentimental work’ to work within a patient’s scope, rather than work limited to the remit of health 
professionals. Indeed, in a self-management care model where much of the day-to- day work of illness 
management is delegated to patients, sentimental work is an important part of that delegated work. 
2. Biographical work was employed by patients to manage changes in their identity brought about by the 
burden of treatment. This builds on Bury’s description of illness work [2] by proposing that, in a 
healthcare model that has added treatment work to a patient’s total self- care workload, patients need to 
engage in biographical work to maintain existing or adapt to new identities caused by treatment-
generated changes. 
3. Relational work was carried out to maintain relationships. Earlier burden of treatment re- search, which 
was more focussed on the planning, doing and monitoring work of treatment [3, 11, 12], has discussed 
the concept of ‘treatment related relational work’. However, this concentrated on the strategic 
mobilisation of others to facilitate treatment. Our review ex- tends this research by addressing the work 
that patients do to minimise the impact of treatment on valued relationships with self and others. In this 
way, patients use relational work to draw on a wider workforce [11, 12, 34] but also to minimise 
relational disruption and maximise the work output from that workforce by maintaining optimal, 
productive and agreeable relationships. 
 
Strategies for minimising treatment disruptions: rationalised non- adherence 
We identified a second strategy to minimise treatment burden: rationalised non-adherence. We found 
that non-adherence was often not an arbitrary act or sign of personal moral failure as it is sometimes 
viewed [35, 36] but a rationalised process, used actively and mindfully, as a way of minimising the burden 
of treatment. Karamanidou, Weinman [28] discusses a similar phenomenon in patients undergoing 
haemodialysis, which they called ‘active non-adherence’. They attributed this non-adherence to beliefs 
about the importance (or not) of treatments, however, we noted non-adherence associated with 
rationalised decisions based on a desire to minimise the disruptions associated with treatment. As a 
result, we have termed this strategy ‘rationalised non-adherence’. Rationalised non-adherence 
occurred when patients, having appraised the impact of treatment, deliberately decided to cease, 
modify or reduce their treatment regime. 
We identified two distinct forms of rationalised non-adherence. We found that in studies which 
included populations approaching the end of life, non-adherence decisions were frequently sanctioned 
and supported by clinicians [24, 29]. Indeed, recent policy and practice initiatives recommend open 
discussion about end of life treatment decisions and include directives to support and endorse patients’ 
decisions, even where these are decisions not to treat [37–39]. This is in contrast to how non-adherence 
was discussed in studies exploring less critical situations [14, 25–28]. We found that rationalised non-
adherence at other points in the illness trajectory or life course was a ‘secret-act’ that must be hidden 
from others. Such (non)- treatment decisions were undertaken covertly, without the knowledge, approval 
or guidance of professionals. This suggests a lack of concordance between patients’ and clinicians’ 
perspectives, which according to our data, results in feelings of guilt. It may also affect patient outcome, 
because important information is withheld that could affect clinical-reasoning and future treatment 
recommendations. Adopting some of the principles of the palliative care approach would facilitate open 
discussion about the impact of treatment burdens and disruption on adherence to treatment, thus 
providing healthcare professionals with an opportunity to consider the 
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balance between treatment burden, adaptation and adherence. Links between treatment bur- den and 
treatment adherence have also been discussed by May, Montori [40] in their seminal text on Minimally 
Disruptive Medicine. They propose that treatment burden can lead to structurally induced non-
compliance as a result of increasingly complex and abundant treatment regimens. In this way, 
structurally induced non-compliance might be viewed as an overarching term linking treatment burden 
with adherence. Our analysis allowed us to explore these links in greater depth and we have shown that 
rather than being solely a response to treatment over- load, non-adherence is often an adaptive and 
rationalised process employed to minimise treatment disruption. 
 
Future developments for BoT research 
Whilst we have been able to partially explain the link between treatment burden, disruption and 
adherence, we have been unable to explore the impact of this non-adherence on relation- ships with 
healthcare professionals and family. The data suggest that rationalised non-adherence necessitates 
further work in the form of concealment, persuasion, and the recruitment of allies among family and 
health professionals. However, further empirical research is required to explore this work in more depth; 
to consider what this work entails, the severity of its consequences for relationships with others and its 
impact on outcomes. 
In addition to extending our understanding of the burden of treatment by contributing to a body of work 
in the field, this review also builds on and adds to recent work on how capacity is expressed by patients. 
May, Eton [33] suggest that in order for functional performance (the potential to do the treatment work 
that needs to be done), patients must mobilise resources from their social capital and secure the 
cooperation of others in their formal and informal social net- work. Doing so is said to allow patients to 
develop structural resilience. In other words, patients must adapt in order to absorb, embed and minimise 
treatment related burden and disruption. This adaptation or ability to absorb adversity is an expression of 
capacity. Our findings support this view by identifying biographical, relational and biological capacity, and 
outlining a number of strategies patients use to adapt to disruptions to these components of their 
capacity. However, we note that these strategies involve work that can generate further burdens and 
disruptions. This may explain why we also identified that in some cases, functional performance is 
deliberately sacrificed for quality of life: rationalised non-adherence means ceasing or modifying some of 
the work of treatment in order to minimise disruption without the additional work of adaptation. Of course, 
rationalised non-adherence is still a form of adaptation, albeit one 
of circumvention. 
 
Conclusions 
This framework synthesis makes a novel contribution to our understanding of treatment bur- den. Using 
evidence from the patient’s perspective we found that treatment burden is experienced as biological, 
biographical and relational disruptions. Patients minimise these disruptions through adaptation and 
rationalised non-adherence. Whilst rationalised non-adherence is supported by HCPs at end-of-life; at 
other times it is a ‘secret-act’ that can generate guilt, disrupt relationships with HCPs and family, and 
ultimately reduce health outcomes. Future work on burden of treatment should consider both treatment 
workload and treatment disruption to fully account for the consequences as well as experiences of 
treatments. Clinicians should engage patients in conversations that allow them to acknowledge treatment 
burden and discuss adherence difficulties without fear of judgement so that appropriate modifications 
can be made to ensure minimally disruptive treatments [33, 40]. Our findings suggest that in order to be 
minimally disruptive, treatments not only have to have a low workload (both duration 
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and complexity), they also have to cause minimal disruption to people’s biographical, relational biological 
capacity. 
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